ATE513855T1 - Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafür - Google Patents
Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafürInfo
- Publication number
- ATE513855T1 ATE513855T1 AT06706157T AT06706157T ATE513855T1 AT E513855 T1 ATE513855 T1 AT E513855T1 AT 06706157 T AT06706157 T AT 06706157T AT 06706157 T AT06706157 T AT 06706157T AT E513855 T1 ATE513855 T1 AT E513855T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- receptor alpha
- receptor
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05000003 | 2005-01-03 | ||
| EP05002229 | 2005-02-03 | ||
| PCT/EP2006/000005 WO2006072564A1 (en) | 2005-01-03 | 2006-01-02 | Antibodies against il-13 receptor alpha 1 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE513855T1 true ATE513855T1 (de) | 2011-07-15 |
Family
ID=36199730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06706157T ATE513855T1 (de) | 2005-01-03 | 2006-01-02 | Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafür |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7807158B2 (de) |
| EP (1) | EP1836226B1 (de) |
| JP (1) | JP5086098B2 (de) |
| KR (1) | KR100934894B1 (de) |
| AR (1) | AR051888A1 (de) |
| AT (1) | ATE513855T1 (de) |
| AU (1) | AU2006204480B2 (de) |
| BR (1) | BRPI0606368A2 (de) |
| CA (1) | CA2592614C (de) |
| CR (1) | CR9209A (de) |
| IL (1) | IL184205A0 (de) |
| MA (1) | MA29226B1 (de) |
| MX (1) | MX2007008128A (de) |
| NO (1) | NO20073655L (de) |
| NZ (1) | NZ556126A (de) |
| RU (1) | RU2413736C2 (de) |
| SG (1) | SG172504A1 (de) |
| TW (2) | TW200902555A (de) |
| WO (1) | WO2006072564A1 (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| LT2769992T (lt) * | 2006-10-02 | 2021-04-12 | Regeneron Pharmaceuticals, Inc. | Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008049098A2 (en) | 2006-10-19 | 2008-04-24 | Merck & Co., Inc. | ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1 |
| EP2068921B1 (de) | 2006-10-19 | 2014-07-09 | CSL Limited | Hochaffine antikörper-antagonisten des interleukin-13-rezeptors alpha 1 |
| DK2068922T3 (da) * | 2006-10-19 | 2012-10-08 | Csl Ltd | Anti-IL-13Ralfa1-antistoffer samt deres anvendelser |
| MX2009012786A (es) | 2007-06-01 | 2009-12-10 | Hoffmann La Roche | Purificacion de inmunoglobulina. |
| CA2693611A1 (en) * | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
| ES2695999T3 (es) | 2007-10-12 | 2019-01-11 | Hoffmann La Roche | Expresión de proteínas a partir de múltiples ácidos nucleicos |
| EP2050764A1 (de) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Neues polyvalentes bispezifisches Antikörperformat und Verwendung |
| US8227195B2 (en) | 2007-12-15 | 2012-07-24 | Hoffman-La Roche Inc. | Distinguishing assay |
| HRP20150965T1 (hr) * | 2009-03-25 | 2015-11-06 | Genentech, Inc. | Anti-fgr3 protutijela i metode koje ih koriste |
| WO2010131704A1 (ja) * | 2009-05-13 | 2010-11-18 | 塩野義製薬株式会社 | 内臓脂肪型肥満の検査薬およびその利用 |
| CA2768326C (en) | 2009-07-30 | 2019-01-08 | F. Hoffmann-La Roche Ag | Moveable chromatography column separator |
| WO2011038894A1 (en) | 2009-10-01 | 2011-04-07 | F. Hoffmann-La Roche Ag | Protein a chromatography |
| PT2483305T (pt) | 2009-10-01 | 2016-11-04 | Hoffmann La Roche | Filtração final de imunoglobulina em várias etapas |
| CN105624118B (zh) | 2009-10-19 | 2019-08-13 | 弗·哈夫曼-拉罗切有限公司 | 非交叉反应性抗IgG抗体 |
| BR112012012873B1 (pt) | 2009-12-22 | 2021-08-31 | F.Hoffmann-La Roche Ag | Método para fornecer uma sequência de ácido nucleico que codifica uma imunoglobulina e método para produzir uma imunoglobulina |
| WO2012022682A1 (en) | 2010-08-17 | 2012-02-23 | F. Hoffmann-La Roche Ag | Anti-human igg1 antibody |
| JP6073811B2 (ja) | 2011-02-02 | 2017-02-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | クロマトグラフィーカラムサポート |
| WO2012145746A1 (en) * | 2011-04-21 | 2012-10-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
| IL312711A (en) | 2012-08-21 | 2024-07-01 | Regeneron Pharma | Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL |
| KR102576903B1 (ko) | 2012-09-07 | 2023-09-13 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| KR20210132232A (ko) | 2013-06-21 | 2021-11-03 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법 |
| BR112015032960B1 (pt) | 2013-07-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| EP4124624A3 (de) | 2013-12-20 | 2023-05-03 | Intervet International B.V. | Antikörper gegen hunde-pd-1 |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| KR102927870B1 (ko) | 2014-02-28 | 2026-02-19 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| CA2961987A1 (en) | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
| WO2016077675A1 (en) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| JP7073253B2 (ja) * | 2015-08-21 | 2022-05-23 | エフ．ホフマン－ラ ロシュ アーゲー | アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法 |
| ES2877532T3 (es) | 2015-08-21 | 2021-11-17 | Hoffmann La Roche | Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| CA3005696A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| WO2018011405A1 (en) * | 2016-07-15 | 2018-01-18 | Universität Zürich | Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia |
| US11771743B2 (en) | 2016-09-01 | 2023-10-03 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| EP3551034A1 (de) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| EP3703818B1 (de) | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r-antagonisten zur verwendung zur behandlung oder verhinderung von asthma |
| EP3768314A4 (de) | 2018-03-21 | 2022-01-05 | ALX Oncology Inc. | Antikörper gegen signalregulatorisches protein alpha und verfahren zur verwendung |
| MA52624A (fr) | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| EP3947457A1 (de) | 2019-03-26 | 2022-02-09 | ASLAN Pharmaceuticals Pte Ltd | Behandlung mit verwendung von anti-il-13r-antikörper oder bindefragment davon |
| CA3147436A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| EP4010373A1 (de) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Verfahren zur behandlung atopischer dermatitis durch verabreichung eines il-4r-antagonisten |
| AU2020325021B2 (en) | 2019-08-05 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
| WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
| TW202333784A (zh) | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | 抗ｉｌ１３ｒ抗體調配物 |
| EP4590335A1 (de) | 2022-08-26 | 2025-07-30 | ASLAN Pharmaceuticals Pte Ltd | Hochkonzentrierte anti-il13r-antikörperformulierung |
| US20260078192A1 (en) | 2022-09-06 | 2026-03-19 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| DE69638050D1 (de) | 1995-10-23 | 2009-11-19 | Zenyth Operations Pty Ltd | Hemopoietin-rezeptor und dafür kodierende genetische sequenzen |
| US5843659A (en) * | 1996-03-21 | 1998-12-01 | Apoptosis Technology, Inc. | Apoptosis gene EI24, compositions, and methods of use |
| JPWO2003046009A1 (ja) * | 2001-11-27 | 2005-04-07 | 持田製薬株式会社 | 抗ＩＬ１３レセプターα１中和抗体 |
| AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| JP4432031B2 (ja) | 2002-03-22 | 2010-03-17 | ズィナイス オペレーションズ ピーティーワイ．エルティーディー． | インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体 |
| US7625699B2 (en) * | 2003-03-10 | 2009-12-01 | Celera Corporation | Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof |
| MEP31508A (hr) * | 2003-07-15 | 2010-10-10 | Amgen Inc | Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade |
-
2005
- 2005-12-30 TW TW097137970A patent/TW200902555A/zh unknown
- 2005-12-30 TW TW094147847A patent/TWI306862B/zh not_active IP Right Cessation
-
2006
- 2006-01-02 BR BRPI0606368-3A patent/BRPI0606368A2/pt not_active IP Right Cessation
- 2006-01-02 CA CA2592614A patent/CA2592614C/en not_active Expired - Fee Related
- 2006-01-02 AT AT06706157T patent/ATE513855T1/de not_active IP Right Cessation
- 2006-01-02 KR KR1020077015296A patent/KR100934894B1/ko not_active Expired - Fee Related
- 2006-01-02 SG SG2009087206A patent/SG172504A1/en unknown
- 2006-01-02 EP EP06706157A patent/EP1836226B1/de not_active Expired - Lifetime
- 2006-01-02 WO PCT/EP2006/000005 patent/WO2006072564A1/en not_active Ceased
- 2006-01-02 JP JP2007548835A patent/JP5086098B2/ja not_active Expired - Fee Related
- 2006-01-02 AU AU2006204480A patent/AU2006204480B2/en not_active Expired - Fee Related
- 2006-01-02 MX MX2007008128A patent/MX2007008128A/es active IP Right Grant
- 2006-01-02 RU RU2007129676/10A patent/RU2413736C2/ru not_active IP Right Cessation
- 2006-01-02 NZ NZ556126A patent/NZ556126A/en not_active IP Right Cessation
- 2006-01-03 AR ARP060100010A patent/AR051888A1/es unknown
- 2006-01-03 US US11/325,197 patent/US7807158B2/en not_active Expired - Fee Related
-
2007
- 2007-06-25 IL IL184205A patent/IL184205A0/en unknown
- 2007-06-26 CR CR9209A patent/CR9209A/es not_active Application Discontinuation
- 2007-07-06 MA MA30048A patent/MA29226B1/fr unknown
- 2007-07-17 NO NO20073655A patent/NO20073655L/no not_active Application Discontinuation
-
2010
- 2010-07-26 US US12/843,225 patent/US20110086026A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200902555A (en) | 2009-01-16 |
| AR051888A1 (es) | 2007-02-14 |
| KR100934894B1 (ko) | 2010-01-07 |
| CA2592614C (en) | 2015-04-14 |
| KR20070091180A (ko) | 2007-09-07 |
| HK1112006A1 (en) | 2008-08-22 |
| TWI306862B (en) | 2009-03-01 |
| BRPI0606368A2 (pt) | 2009-06-23 |
| JP2008526187A (ja) | 2008-07-24 |
| NO20073655L (no) | 2007-08-02 |
| MX2007008128A (es) | 2007-07-20 |
| CA2592614A1 (en) | 2006-07-13 |
| US20110086026A1 (en) | 2011-04-14 |
| CR9209A (es) | 2007-08-28 |
| US20060263356A1 (en) | 2006-11-23 |
| JP5086098B2 (ja) | 2012-11-28 |
| RU2413736C2 (ru) | 2011-03-10 |
| EP1836226A1 (de) | 2007-09-26 |
| WO2006072564A1 (en) | 2006-07-13 |
| IL184205A0 (en) | 2007-10-31 |
| NZ556126A (en) | 2008-09-26 |
| EP1836226B1 (de) | 2011-06-22 |
| TW200635945A (en) | 2006-10-16 |
| RU2007129676A (ru) | 2009-02-10 |
| MA29226B1 (fr) | 2008-02-01 |
| AU2006204480A1 (en) | 2006-07-13 |
| AU2006204480B2 (en) | 2011-06-09 |
| SG172504A1 (en) | 2011-07-28 |
| US7807158B2 (en) | 2010-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2025024I2 (el) | Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων | |
| LTC2474557I2 (lt) | Anti-cd79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai | |
| ATE538137T1 (de) | Antikörper gegen menschliches il-22 und verwendungen davon | |
| PT1920065T (pt) | Anticorpos anti-alfavbeta6 e suas utilizações | |
| ATE523524T1 (de) | Antikörper und immunkonjugate gegen tat226 | |
| HRP20220755T3 (hr) | Anti-gm-csf antitijela i njihova uporaba | |
| IL184205A0 (en) | Antibodies against il-13 receptor alpha 1 and uses thereof | |
| NO20082454L (no) | Anti-alfa2 integrin antistoffer og deres anvendelser | |
| ATE456581T1 (de) | Antikörper gegen il21-rezeptor und deren verwendung | |
| ATE550355T1 (de) | Antikörper gegen ccr5 und ihre verwendung | |
| DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
| DK2222706T3 (da) | Antibodies against human nkg2d and uses thereof | |
| PL2502938T3 (pl) | Przeciwciała i immunokoniugaty oraz ich zastosowanie | |
| ATE501174T1 (de) | Antikörper gegen madcam | |
| PT2059535E (pt) | Anticorpos específicos do prlr e suas utulizações | |
| DK2209806T3 (da) | Anti-hepcidin-antistoffer og anvendelser deraf | |
| EP2122054A4 (de) | Vliestafel und konstruktionsverfahren dafür | |
| EP2083121A4 (de) | Aus polymermodifziertem zement hergestellte porenbeton-strassendeckenstruktur und konstruktionsverfahren dafür | |
| DE602007009443D1 (de) | Nanodrahtzusammensetzung und Herstellungsverfahren dafür | |
| ATE531712T1 (de) | Substituierte aryloxazole und ihre verwendung | |
| DE602005023639D1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
| EP1746902A4 (de) | Multilektin-affiniätschromatografie und verwendung dafür | |
| DE502007001209D1 (de) | Wachszusammensetzung und deren Verwendung | |
| EP1818468A4 (de) | Konstruktionsmaterial und gebäude | |
| ATE511507T1 (de) | Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |